Oral fluoroquinolones represent the first choice of treatment for patients with documented chronic bacterial prostatitis (CBP), and the recommended duration is at least 4 weeks. Since the various available drugs present different pharmacokinetic and pharmacodynamic properties and different microbial resistance profiles, the aim of the present study is to compare the efficacy and safety of Prulifloxacin, a new broad-spectrum oral fluoroquinolone with long half-life and high urinary concentrations, with those of Levofloxacin in the treatment of men with CBP.

Material & Methods: A total of 96 consecutive patients with a clinical diagnosis of CBP and current laboratory evidence of infection were randomized to receive a 4-week oral course of either Prulifloxacin 600 mg or Levofloxacin 500 mg once daily. All subjects were evaluated with the Meares-Stamey test and the validated Italian version of the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) at baseline and one week after therapy completion. Patients with microbiologic eradication were evaluated for recurrent infection with the Meares-Stamey test 6 months after therapy completion. The primary end point was microbiologic eradication. The secondary end points were clinical efficacy, assessed by reduction in the NIH-CPSI, recurrent infection rate at 6 months, and safety.

Results: The microbiologic eradication rate was 72.73% for Prulifloxacin and 71.11% for Levofloxacin (p=0.86). The clinical success rate was not significantly different, since the reduction in the NIH-CPSI score from study entry to study completion was 10.75 (from 17.22 to 6.47) for Prulifloxacin and 10.73 (from 17.33 to 6.6) for Levofloxacin (p=0.98). After 2 weeks of treatment there was a trend toward a greater reduction of the symptom score for Prulifloxacin (5.29) than for Levofloxacin (4.80) (p=0.105). At 6 months a lower proportion of patients on Prulifloxacin (n=5) had a positive Meares-Stamey test compared to Levofloxacin (n=11), the difference being only marginally significant (p=0.008). Safety was comparable in the two groups, with a rate of treatment-related adverse events of 18.16% for Prulifloxacin and 22.22% for Levofloxacin (p=0.79).

Conclusions: The present results suggest that Prulifloxacin 600 mg orally once daily is at least as effective and safe as Levofloxacin 500 mg orally once daily administered for 4 weeks in the treatment of men with CBP. Therapy with both drugs enables the great majority of patients to achieve microbiological eradication of the infecting strain and to significantly improve the symptom complex. Recent studies have shown that the active metabolite of Prulifloxacin has a greater tendency than the other fluoroquinolones to penetrate within both bacteria and phagocytic cells, and this is reflected by a trend toward an earlier resolution of subjective symptoms.

ARTERIAL HEMODYNAMIC OF THE PROSTATE AND NEUROPHYSIOLOGY OF PELVIC FLOOR AT PATIENTS WITH CP/CPPS III AND EFFICIENCY ANALGESIC PREPARATIONS

Kogan M.1, Belousov L.1, Shangichev A.2, Palenyj A.1, Afoko P.1
1Rostov State Medical University, Urology, Rostov on Don, Russia, 2Rostov State Medical University, Diagnostic Radiology, Rostov on Don, Russia

Introduction & Objectives: The contemporary investigations of the pathogenesis of Chronic Pelvic Pain Syndrome (CP/PSPS) have shown that in the inflammatory (IIIA) CP/PSS the basis of the pain syndrome is inflammation, whilst in the non-inflammatory (IIIB) CP/PSS vascular and neurological factors are responsible. The primary intent of the CP/PSS III B therapy is correction of the pain syndrome.

Material & Methods: We’ve investigated the intrasorganic prostate hematokinetic (the density of bloodstream and the top indices of the arterial blood flow speed), the neurophysiology of the pelvic floor’s muscles and compared the efficacy specimen with different mechanism of action in the pain syndrome’s therapy, which have patients with CP/CPPS III B. 65 patients with diagnosis CP/CPPS III B and pain quantification in Visual Analog Scale (VAS) 4-8 have been analyzed. There were 30 patients in the group with the form III A: 35 patients in the group with the form III B. In the control group were 13 healthy volunteers. All patients were 20-40 years old. 32 patients with CP/CPPS III B had therapy for 12 weeks: 12 patients took Flupirtin 100 mg 4 x 4 times per day; 10 patients took Celexcoxib 200 mg x 1 time per day. The effects of the drugs were assessed at 1, 4 and 8 weeks of therapy using theVAS and compared with placebo (10 patients).

Results: Hemodynamic parameters in the group IIIA were statistically doubtful (p=0.05) and smaller than in the control, but reduced in all quantifications. Patients with IIIB in 88.6% of cases had hemodynamic parameters, which were smaller than more than 50% in control (p<0.01). At the same time the amplitude of the potential of the motor unit (PMU) was increased in 58.3% of cases (1087.2 ± 53.6 µV) and high-amplitude PMU (>1000 µV) was recorded in 50% of cases. The increase the bulbocavernous reflex > 41 m/sec was recorded in 56.3% of cases and reduction cortical somato-sensory potentials that were generated by stimulating the pudendal nerve in 75% of cases. The bigger analgesic effect was reached in the group of patients with Flupirtin. Intensity of pain was reduced by 8 week at 67.2% in placebo group, in the group with Celexcoxib reduction was 43.7%.

Conclusions: The reduction of blood flow’s speed against a background reduction of bloodstream’s density by CP/CPPS IIIB indicate organ ischemia. Our investigations revealed sub-clinical pathologies in patients with CP/PSS IIIB in 66.7% cases. Among these 75.0% are seen to have peripheral neuropathy and 41.7% have pudendal axonopathy. Analgesic effect of both pharmacologic preparations was observed already by the end of the first week and continued to rise right up to the eighth week of investigation. Flupirtin had a better clinical effect compared to Celexcoxib.

PHYSICAL ACTIVITY FOR MEN WITH CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME NOT SATISFIED WITH CONVENTIONAL TREATMENTS: COULD IT REPRESENT A VALID OPTION? THE PHYSICAL ACTIVITY AND MALE PELVIC PAIN TRIAL: A DOUBLE BLOIND, RANDOMIZED STUDY

Giubilei G.1, Mogorovich A.1, Valenti F.2, Morelli G.3, De Maria M.3, Manassero F.1, Barbone F.1, Sellì C.1
1University of Pisa, Urology, Pisa, Italy, 2University of Udine, Epidemiology, Udine, Italy

Introduction & Objectives: Chronic pelvic pain syndrome (CPPS) is a major health problem due to the patient’s quality of life is poor and currently no investigated therapies have significant long-term benefit. We performed a preliminary investigation of the role of physical activity and its effects on select patients with chronic prostatitis/chronic pelvic pain syndrome.

Material & Methods: Between 2002 and 2004 we recruited a volunteer sample of 231 eligible males 20 to 50 years old with chronic prostatitis/chronic pelvic pain syndrome who were unresponsive to conventional treatments and free of any contraindication for moderate intensity physical exercise. This group was screened and, if in accordance with the study inclusion/exclusion criteria, patients were randomized into 2 groups. Participants were randomly assigned to the aerobic exercise group (52) and the placebo/stretching and motion exercises group (51). Main outcome measures were the Italian version of the National Institutes of Health Chronic Prostatitis Symptom Index, Beck Depresstion Inventory, State Anxiety Inventory-Y and a pain intensity visual analog scale administered at baseline, and 6 and 18 weeks.

Results: At 18 weeks 36 subjects (75%) in the aerobic exercise group vs 40 (81.6%) in the placebo/stretching and motion exercises group completed the 18-week program and evaluation. Differences between the 2 groups were found in total National Institutes of Health Chronic Prostatitis Symptom Index, pain and quality life impact subscales, and pain visual analog score (ANOVA F=0.008, 0.0009, 0.02 and 0.003 respectively).

Conclusions: Improvements in the aerobic exercise group were significantly superior compared to those in the placebo/stretching and motion exercises group. Aerobic exercise represents a valid treatment option and it should be further investigated in a larger study with longer followup.

ESTIMATION OF STANDARD THERAPY CHRONIC PELVIC PAIN SYNDROM (CP/CPPS III) AT MEN

Kogan M.1, Shangichev A.2, Mikashinovich Z.2, Chemogubova E.1, Shimunov G.2, Belousov L.1, Afoko P.1
1Rostov State Medical University, Urology, Rostov on Don, Russia, 2Rostov State Medical University, Biochemistry, Rostov on Don, Russia, 3Southern Russian Research Centre of the Russian Academy of Science, Urology, Rostov on Don, Russia

Introduction & Objectives: The Activation of kallikrein-kinin system (KKS) in the blood is a biochemical marker of intensity of inflammatory process in the prostate. The nitric oxide (NO) stars in the mechanisms of development of inflammation. The purpose of the research is to develop criterion of monitoring efficiency of treatment inflammatory and aninflammatory forms CP/CPPS.

Material & Methods: Some parameters KKS of bloods and NO- systems in the placebo/stretching and motion exercises group were evaluated for recurrent infection with the Meares-Stamey test 6 months after therapy completion. The primary end point was microbiologic eradication. The secondary end points were clinical efficacy, assessed by reduction in the NIH-CPSI, recurrent infection rate at 6 months, and safety.

Results: The reduction of blood flow’s speed against a background reduction of bloodstream’s density by CP/CPPS IIIB indicate organ ischemia. Our investigations revealed sub-clinical pathologies in patients with CP/PSS IIIB in 66.7% cases. Among these 75.0% are seen to have peripheral neuropathy and 41.7% have pudendal axonopathy. Analgesic effect of both pharmacologic preparations was observed already by the end of the first week and continued to rise right up to the eighth week of investigation. Flupirtin had a better clinical effect compared to Celexcoxib.

Conclusions: The activation of kallikrein-kinin system (KKS) in the blood is a biochemical marker of intensity of inflammatory process in the prostate.